Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes Mellitus: A Comprehensive Review of How to Weigh the Options, Select the Right Patients, and Maximize Benefits
 
Release Date: November 5, 2018
Expiration Date: November 5, 2019
Time to Complete Activity: 1.0 hour

*This activity expired for credit on November 5, 2019 and is no longer available for credit
 

Faculty
Lawrence Blonde, MD, FACP, MACE
Director, Ochsner Diabetes Clinical Research Unit,
Frank Riddick Diabetes Institute,
Department of Endocrinology,
Ochsner Medical Center
New Orleans, LA

Vivian Fonseca, MD
Tullis–Tulane Alumni Chair in Diabetes
Professor of Medicine and Pharmacology
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, LA
 
This activity is provided by the American Association of Clinical Endocrinologists.  
 
Program management services provided by Paradigm Medical Communications, LLC.  
 
Target Audience
This activity has been designed to address the educational needs of endocrinologists and other specialists who manage patients with type 2 diabetes. It will also benefit other healthcare professionals, such as primary care physicians, certified diabetes educators, nurse practitioners, and PAs, who are interested in the management of patients with type 2 diabetes.
 
Statement of Need
Despite demonstration of robust glycemic and extraglycemic benefits, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remain underutilized in type 2 diabetes mellitus (T2DM). A confluence of data and expert opinion strongly point to both the desire and need for specialist education on the intensification of T2DM treatment plans that include GLP-1 RAs, when appropriate, to enhance patient outcomes. This educational activity will address the nuances of GLP-1 RA therapy, providing a scientific, guideline-based, and expert-endorsed foundation for differentiating and selecting among current and emerging options, including newly available fixed-ratio insulin/GLP-1 RA injection combinations, with an emphasis on the most recent data. It will also provide strategies for overcoming barriers to injectable therapy.
 
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
  • Describe the mechanisms by which current and emerging glucagon-like peptide-1 receptor agonists exert beneficial effects on patients with type 2 diabetes.
  • Differentiate among the current and emerging glucagon-like peptide-1 receptor agonists based on pharmacology, dosing, efficacy, safety, and extraglycemic effects.
  • Select appropriate candidates for glucagon-like peptide-1 receptor agonist therapy based on: current recommendations derived from guidelines, algorithms, and position statements; agent properties; and patient characteristics and preferences.
  • Outline clinician-patient communication strategies to initiate and foster patient adoption of, and adherence to, appropriate, individualized antihyperglycemic treatment.
 
Physician Accreditation Statement
The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Physician Credit Designation Statement
The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
 
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.  Individuals are responsible for checking with the AANPCP for further guidelines.

For information about the accreditation of this CME activity, please contact the AACE CME Department at cme@aace.com or (904) 353-7878.
 
Disclosure of Commercial Support
This activity is supported by an educational grant from Novo Nordisk Inc.
 
Instructions for Participation
To receive a CME certificate of participation, you should:
  • Read the entire publication, including the Continuing Medical Education information.
  • Register or log in at www.paradigmmc.com/657 to complete and submit the online posttest and evaluation OR complete the posttest/evaluation form at the end of the article and mail or fax it to Paradigm Medical Communications, LLC, 523 Route 303, Orangeburg, NY 10962; fax (845) 398-5108.
  • Answer 70% of the posttest questions correctly to earn credit. Online completion of the posttest allows unlimited opportunities to successfully complete the posttest.
Following online completion of the posttest and evaluation, a certificate of participation will be available for download/printing immediately. Participants who submit a posttest/evaluation form via mail or fax will receive an email with a link to their certificate of participation within 1 to 2 weeks following receipt of completed form.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
 
There is no fee required for participation in this activity.
 
Hardware/Software Requirements
This activity is in Adobe Acrobat PDF format. To view the activity, you will need Adobe Reader. If you do not have Adobe Reader installed on your computer, please visit http://get.adobe.com/reader/ to install a free version of Adobe Reader.
 
Supported Browsers:
For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
 
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

Technical Support: If you have any technical problems or playback issues email us at contactus@paradigmmc.com.
 
Declaration of Disclosure and Conflicts of Interest
It is the policy of AACE to ensure balance, independence, objectivity, and scientific rigor in all of its CME activities.  Presentation content may include discussion of an unlabeled use of a commercial product or an investigational use of a product not yet approved for any purpose.  AACE requires that participating faculty disclose to the audience any product(s) and its use(s) discussed in the educational activity that are unapproved/unlabeled for the use by the FDA or still considered investigational in nature. 
 
Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships. “Relevant financial relationships” are financial relationships in any amount occurring within the past 12 months that create a conflict of interest.  AACE requires speakers, faculty, CME Committee, and other individuals who are in a position to control the content of this educational activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity.  All identified conflicts of interest are thoroughly evaluated by AACE for fair balance, scientific objectivity of studies mentioned in the presentation, and educational materials used as basis for content, and appropriateness of patient care recommendations. 
 
The intent of this disclosure is not to prevent a speaker with commercial affiliations from presenting, but rather to provide learners with information from which they may make their own judgments.  Informed learners are the final safeguards in assuring that a CME activity is independent from commercial influence. 
 
CME Accreditation Committee
Myriam Allende-Vigo, MD, MBA, FACP, FACE
Advisory Honoraria: Merck & Co., Inc.
 
Joshua I. Barzilay, MD, FACE
Dividends: Abbvie; Bristol Myers Squibb; Merck & Co., Inc.; Pfizer; Sanofi; Teva
 
Tamis Bright, MD
Salary: Southwest ENT (Spouse)
 
Ricardo Correa, MD
No financial relationships to disclose
 
Diane Donegan, MBChB
No financial relationships to disclose
 
Kurt Kennel, MD, FACE
No financial relationships to disclose
 
Phillip D.K. Lee, MD, FACE
No financial relationships to disclose
 
Philip Raskin, MD, FACE
Grant/Research Support: Amylin Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; Gan & Lee Pharmaceuticals
Honoraria for Consulting and Lectures: Intarcia; Reata Pharmaceuticals
 
Jad Sfeir, MD
No financial relationships to disclose
 
Jagdeesh Ullal, MD, FACE, ECNU
No financial relationships to disclose
 
Rong Mei Zhang, MD
No financial relationships to disclose
 
Faculty
Lawrence Blonde, MD, FACP, MACE
Grant/Research Support: AstraZeneca; Janssen Pharmaceuticals, Inc; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc; Novo Nordisk Inc.; sanofi-aventis U.S. LLC
Honoraria for Consulting and Lectures: AstraZeneca; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals, Inc; Merck & Co., Inc; Novo Nordisk Inc.; sanofi-aventis U.S. LLC

Vivian Fonseca, MD, FRCP
Grant/Research Support: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc
Honoraria for Consulting and Lectures: Asahi-Kasei Pharma; AstraZeneca; Eli Lilly and Company; Intarcia Therapeutics, Inc.; Novo Nordisk Inc.; sanofi-aventis U.S. LLC; Takeda Pharmaceutical Company Ltd
 
Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose.

The American Association of Clinical Endocrinologists staff members have no financial relationships to disclose.  

Independent peer reviewer has no financial relationships to disclose.
 
Resolution of Conflict of Interest
The American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC, have implemented a system to resolve conflicts of interest for each CME activity to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
 
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
 
Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, the American Association of Clinical Endocrinologists or Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
 
As ACCME-accredited providers, the American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC, activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by the American Association of Clinical Endocrinologists or Paradigm Medical Communications, LLC.
 
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of the American Association of Clinical Endocrinologists or Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by the American Association of Clinical Endocrinologists or Paradigm Medical Communications, LLC. The American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC, accepts no liability for the content referenced in this activity.

Privacy policy
The American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC, are committed to protecting the privacy of those who participate in the activities (herein referred to as “website") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
 
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
 
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by the American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC, to continuously improve the learning experience.
 
The American Association of Clinical Endocrinologists or Paradigm Medical Communications, LLC, does not transfer, sell, or share personal information with outside parties. The American Association of Clinical Endocrinologists or Paradigm Medical Communications, LLC, will not otherwise disclose personal information unless required to in a legal process. The American Association of Clinical Endocrinologists and Paradigm Medical Communications, LLC, staff members review individual test results to the extent necessary to record and track participants’ credits.
 
Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.
 
© 2018 AACE.  All rights reserved.  No part of this enduring material may be reproduced or transmitted in any other form or by any other means, electronic or mechanical, without first obtaining written permission from AACE.

                                           LEARNER BILL OF RIGHTS
 
 
 
The American Association of Clinical Endocrinologists (AACE) recognizes that you are a life-long learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge, skill or performance.  As part of AACE’s duty to you as a learner, you have the right to expect that your continuing medical education experience with AACE includes:
 
CONTENT that:
  • Promotes improvements or quality in healthcare;
  • Is valid, reliable and accurate;
  • Offers balanced presentations that are free of commercial bias for or against a product/service;
  • Is vetted through a process that resolves any conflicts of interests of planners, teachers or authors;
  • Is driven and based on learning needs, not commercial interests;
  • Addresses the stated objectives or purpose; and
  • Is evaluated for its effectiveness in meeting the identified educational need.
 
A LEARNING ENVIRONMENT that:
  • Supports learners’ ability to meet their individual needs;
  • Respects and attends to any special needs of the learners;
  • Respects the diversity of groups of learners; and
  • Is free of promotional, commercial and/or sales activities.
 
DISCLOSURE of:
  • Relevant financial relationships planners, teachers and authors have with commercial interests related to the content of the activity; and
  • Commercial support (funding or in-kind resources) of the activity.